April 2, 2026
The Valley Hospital is pleased to be the first hospital in the United States to use Rapiblyk® (landiolol) to treat cardiac arrhythmias among the critically ill patient population. The cardiac critical care team at The Valley Hospital administered the medication as a treatment for atrial fibrillation with a rapid heart rate.
Landiolol is a fast-acting, intravenous beta blocker indicated for the short-term reduction of ventricular rate (the number of times the heart's ventricles contract per minute) in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter as well as pediatric patients with supraventricular tachycardia – according to manufacturer AOP Orphan Pharmaceuticals GmbH (AOP Health US). The medication is administered intravenously – via an IV line – in the inpatient hospital setting, often in critical care situations.
The medication had been approved for use in Europe, Japan, and Canada, and was FDA-approved for use in the United States in November 2024.
“We are excited to be at the forefront of caring for critically ill patients with cardiac arrhythmia by making new treatment options available to our patients at The Valley Hospital,” said Yonathan Litwok, MD, Director of Cardiac Critical Care at The Valley Hospital. “Valley’s cardiac critical care team stays up to date with the latest innovations and treatments in our field, to provide our patients with high-quality care.”
Cardiac critical care is a specialized type of care for patients with conditions that are life-threatening or complicated and require intensive monitoring, advanced therapies, and rapid intervention. The cardiac critical care team demonstrates highly coordinated, team-based care to quickly stabilize patients. The team also clearly communicates with the patient and their loved ones to ensure their needs are met.
“I am proud of the continued innovation displayed by our team at The Valley Hospital,” said Suneet Mittal, MD, Chair of the Cardiovascular Service Line for Valley Health System. “We will continue to seek new treatments and therapies to advance the high-quality care we are able to offer our patients.”
For more information about the cardiac intensive care unit at Valley, please visit ValleyHealth.com/CICU.
About AOP Health Group and AOP Health US, LLC
AOP Health Group is a global enterprise with roots in Austria and a mission to address unmet medical needs through innovative, science-driven therapies in cardiovascular and rare disease. Since 1996, the AOP Health Group has been recognized as a pioneer in developing integrated therapy solutions that combine deep scientific expertise with a strong commitment to patient and physician needs.
Building on this foundation, AOP Health US, LLC was established in 2025 to expand the AOP Health Group’s impact in the United States. AOP Health US is committed to furthering AOP Health Group’s vision of advancing care, improving outcomes, and strengthening trust across the healthcare community.